Aquestive is seeking FDA approval for its product Anaphylm, with data presented at a conference in Chicago.
3 reports, 1 independent
Updated Sep 8
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Aquestive is seeking FDA approval for its product Anaphylm, with data presented at a conference in Chicago.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Aquestive (United States)
company in Warren Township, United States
Nothing else this week.
- FDA
Related events
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
Coverage
Newest first; wire copies grouped- insidermonkey.com
- Unknown outlet